Which patients could benefit the most from bioresorbable vascular scaffold implant: From clinical trials to clinical practice

Minerva Cardioangiologica

Volumn 61, Issue 3, 2013, Pages 255-262

  Latib, A ^a   Costopoulos, C ^a   Naganuma, T ^b   Colombo, A ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

Drug eluting stents; Myocardial revascularization; Stents; Thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN; TISSUE SCAFFOLD;

BIORESORBABLE VASCULAR SCAFFOLD IMPLANT; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; METAL STENT; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR IMPLANT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RISK FACTORS; STENTS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84879750036     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Konig A, Schiele TM, Rieber J, Theisen K, Mudra H, Klauss V. Influence of stent design and deployment technique on neointima formation and vascular remodeling. Z Kardio 2002;91(Suppl 3):98-102. (Pubitemid 34809732)
2. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. JACC 2011;57:1314-22.
3. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5. (Pubitemid 38222887)
4. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): a prospective open label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
5. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
6. Serruys PW, Onuma Y. On behalf of the ABSORB A & B investigators. ABSORB Cohort B: 6 m, 12 m, 18 m and 24 m follow-up. Presented at: PCR focus group on bioresorbable vascular scaffolds. Rotterdam, NL, March 2012.
7. Bartotelli A. An Interim Report on the 12-Month Clinical Outcomes from the First 250 Patients Registered. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, October 2012.
8. Verheye S. On behalf of the DESolve investigators. First-in-Man Results with a Myolimus-Eluting Bioresorbable PLLA-based Vascular Scaffold (Elixir DESolve). Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, October 2012.
9. Costa R. REVA ReZolve Clinical Program Update.Presented at:Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, October 2012.
10. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75. (Pubitemid 46829357)
11. Haude M. Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK Dreams Program): DREAMS 2-Year Results. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, October 2012.
12. Colombo A, Latib A. Can long-term results following balloon angioplasty be the "crystal ball" to predict outcome following bioresorbable vascular scaffolds? J Am Heart Assoc 2012;1:e005272.